Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome
- Authors: Reshetnyak T.M.1,2, Cheldieva F.A.1,2, Cherkasova M.V.1, Lila A.M.1,2, Nasonov E.L.1,3
-
Affiliations:
- Nasonova Research Institute of Rheumatology
- Russian Medical Academy of Continuous Professional Education
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 94, No 5 (2022)
- Pages: 628-634
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/108779
- DOI: https://doi.org/10.26442/00403660.2022.05.201488
- ID: 108779
Cite item
Full Text
Abstract
Aim. To determine the significance of antibodies to the phosphatidylserine/prothrombin complex (aPS/PT) in patients with systemic lupus erythematosus (SLE) antiphospholipid syndrome (APS).
Materials and methods. A total of 190 patients were included in the study: 123 (64.7%) with reliable SLE and 55 (29%) with PAPS. The control group included 100 relatively healthy subjects of comparable age. All patients were tested for classical aPL as well as IgG/IgM-anti-PS/PT by enzyme immunoassay.
Results. Based on the average values of IgG/IgM aPS/PT of the control group, the levels of positivity were allocated mean (M) + 3 or 5 standard deviations (SD): M+3SD and M+5SD. IgG aPS/PT levels above 73.6 U/ml (M+5SD) were more accurate diagnostic, for IgM aPS/PT – above 18.0 U/ml. IgG-aPS/PT were detected in 84 (44%) of 190 patients. Levels above diagnostic levels were detected in 68 (65%) of 104 patients with APS (55 with PAPS and 59 with SLE+APS). Thrombosis was significantly more common in patients with IgG aPS/PT compared with patients negative for IgG aPS/PT. Arterial but not venous thrombosis was associated with IgG aPS/PT positivity.
Conclusion. The frequency of detection of IgG aPS/PT in the examined patients was 44%, IgM aPS/PT – 29% and their combination – 19% of 190 patients. Half of the patients with probable APS had positive IgG aPS/PT and third – IgM aPS/PT. Median IgG aPS/PT were significantly higher in patients with APS compared to patients without APS and the control group. Thrombosis was associated with IgG aPS/PT. Arterial thrombosis was significantly more frequently reported in patients with IgG aPS/PT. The sensitivity of IgG aPS/PT for reliable APS at levels greater than 73.6 units/ml was 59%, specificity – 92%, for IgM aPS/PT – 35% and 91%, respectively.
Full Text
##article.viewOnOriginalSite##About the authors
Tatiana M. Reshetnyak
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: t_reshetnyak@yahoo.com
ORCID iD: 0000-0003-3552-2522
д-р мед. наук, проф., зав. лаб. тромбовоспаления ФГБНУ «НИИ ревматологии им. В.А. Насоновой», проф. каф. ревматологии ФГБОУ ДПО РМАНПО
Russian Federation, Moscow; MoscowFariza A. Cheldieva
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Email: t_reshetnyak@yahoo.com
ORCID iD: 0000-0001-5217-4932
мл. науч. сотр. лаб. тромбовоспаления ФГБНУ «НИИ ревматологии им. В.А. Насоновой», аспирант каф. ревматологии ФГБОУ ДПО РМАНПО
Russian Federation, Moscow; MoscowMariya V. Cherkasova
Nasonova Research Institute of Rheumatology
Email: t_reshetnyak@yahoo.com
ORCID iD: 0000-0002-3246-1157
канд. биол. наук, врач клинической лабораторной диагностики, науч. сотр. лаб. тромбовоспаления ФГБНУ «НИИ ревматологии им. В.А. Насоновой»
Russian Federation, MoscowAleksander M. Lila
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Email: t_reshetnyak@yahoo.com
ORCID iD: 0000-0002-6068-3080
д-р мед. наук, проф., дир. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», зав. каф. ревматологии ФГБОУ ДПО РМАНПО
Russian Federation, Moscow; MoscowEvgeny L. Nasonov
Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)
Email: t_reshetnyak@yahoo.com
ORCID iD: 0000-0002-1598-8360
акад. РАН, д-р мед. наук, проф., науч. рук. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», зав. каф. ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, Moscow; MoscowReferences
- Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010-21. doi: 10.1056/NEJMra1705454
- Насонов Е.Л. Антифосфолипидный синдром. М.: Литтера, 2008 [Nasonov EL. Antifosfolipidnyi sindrom. Moscow: Littera, 2008 (in Russian)].
- Решетняк Т.М., Чельдиева Ф.А., Нурбаева К.С., и др. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;4:4-21 [Reshetnyak TM, Cheldieva FA, Nurbaeva KS, et al. Antiphospholipid syndrome: diagnosis, mechanism of development, therapy issues. Tromboz, gemostaz i reologiya. 2020;4:4-21 (in Russian)]. doi: 10.25555/THR.2020
- Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103. doi: 10.1038/nrdp.2017.103
- Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71 (in Russian)].
- Чельдиева Ф.А., Решетняк Т.М., Лила А.М. Антифосфолипидные антитела и их клиническое значение. Тромбоз, гемостаз и реология. 2021;(2):4-15 [Cheldieva FA, Reshetnyak TM, Lila AM. Antiphospholipid antibodies and their clinical significance. Tromboz, gemostaz i reologiya. 2021;(2):4-15 (in Russian)].
- Radin M, Cecchi I, Foddai SG, et al. Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-Phosphatidyl Serine/Prothrombin Antibodies. Biomedicines. 2020;8(12):622. doi: 10.3390/biomedicines8120622
- Devreese KMJ. How to Interpret Antiphospholipid Laboratory Tests. Curr Rheumatol Rep. 2020;22(8):38. doi: 10.1007/s11926-020-00916-5
- Antovic A, Norberg EM, Berndtsson M, et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb Haemost. 2017;117(9):1700-4. doi: 10.1160/TH17-03-0204
- Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737-40. doi: 10.1111/j.1538-7836.2009.03555.x
- Chaudhary R, Sharma T, Garg J, et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis. 2020;49(2):271-86. doi: 10.1007/s11239-019-01954-2
- Hoxha A, Banzato A, Ruffatti A, Pengo V. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev. 2017;16(2):173-8. doi: 10.1016/j.autrev.2016.12.010
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x
- Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928
- Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630-40. doi: 10.1002/art.1780350606
- Bajaj SP, Rapaport SI, Fierer DS, et al. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood. 1983;61(4):684-92.
- Oosting JD, Derksen RH, Entjes HT, et al. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost. 1992;67(5):499-502.
- Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988;72(2):512-9.
- Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005;93(2):289-97. doi: 10.1160/TH04-06-0382
- Bardin N, Alessi MC, Dignat-George F, et al. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis? Immunobiology. 2007;212(7):557-65. doi: 10.1016/j.imbio.2007.02.001
- Žigon P, Čučnik S, Ambrožič A, et al. Antibodies to phosphatidylserine/prothrombin complex as an additional diagnostic marker of APS? Lupus. 2012;21(7):790-2. doi: 10.1177/0961203312444173
- Shi H, Zheng H, Yin YF, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(4):614-24. doi: 10.1515/cclm-2017-0502
- Ruffatti A, Del Ross T, Ciprian M, et al; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70(6):1083-6. doi: 10.1136/ard.2010.142042
- Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13(6):595-608. doi: 10.1016/j.autrev.2013.11.004
- Sciascia S, Sanna G, Murru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354-64. doi: 10.1160/TH13-06-0509
- Sciascia S, Sanna G, Murru V, et al. GAPSS: The Global Anti-Phospholipid Syndrome Score. Rheumatology (United Kingdom). 2013:52(8):1397-403. doi: 10.1093/rheumatology/ kes388
- Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504-12. doi: 10.1002/art.33340
- Sciascia S, Murru V, Sanna G, et al. Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities. J Thromb Haemost. 2012;10(12):2512-8. doi: 10.1111/jth.12014
- Fabris M, Giacomello R, Poz A, et al. The Introduction of Anti-Phosphatidylserine/Prothrombin Autoantibodies in the Laboratory Diagnostic Process of Anti-Phospholipid Antibody Syndrome: 6 Months of Observation. Autoimmun Highlights. 2014;5(2):63-7. doi: 10.1007/s13317-014-0061-3
- Sciascia S, Radin M, Cecchi I, et al. Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. Front Immunol. 2019;10:376. doi: 10.3389/fimmu.2019.00376
- Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies-are they worth assaying? Thromb Res. 2004;114(5-6):533-8. doi: 10.1016/j.thromres.2004.08.024; PMID: 15507288